---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-039009"
form_type: "8-K"
ticker: "PLUR"
cik: "0001158780"
company_name: "Pluri Inc."
filed_at: "2022-07-13T23:59:59+00:00"
generated_at: "2026-06-24T15:40:21.849251+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pluristem Phase III hip fracture study misses primary endpoint but meets key secondary muscle strength measure

## Summary
- Primary endpoint SPPB at week 26 not met; PLX-PAD showed no significant improvement vs placebo.
- Hip Abduction Strength (HAS) significantly improved: injured leg +2kg at wk26 (p=0.047) and +4kg at wk52 (p=0.0022).
- Uninjured leg also benefited: +1.8kg at wk26 (p=0.073) and +4kg at wk52 (p=0.0046) vs placebo.
- 6-minute walk test at wk52: PLX-PAD patients walked 296m vs 266m for placebo (positive trend).
- Company plans to seek regulatory advice and explore partnerships to advance PLX-PAD development.

## SEC filing metadata
- accession: 0001213900-22-039009
- form_type: 8-K
- ticker: PLUR
- cik: 0001158780
- company_name: Pluri Inc.
- filed_at: 2022-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158780/000121390022039009/0001213900-22-039009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158780/000121390022039009/ea162806-8k_pluristem.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-039009
- JSON: https://secwatch.observer/filing/0001213900-22-039009.json
- Plain text: https://secwatch.observer/filing/0001213900-22-039009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.